Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday.

Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an eye out for. In a perfect world, we'd like to see a company investing more ...

Inspire Medical Systems, Inc. announced preliminary fourth quarter and full year 2024 financial results, revealing anticipated revenues of approximately $239.5 million to $239.7 million for Q4 ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Inspire Medical Systems (INSP – Research Report) yesterday and set a price ...

Investing.com -- Shares of Inspire Medical Systems, Inc. (NYSE:INSP) fell 11% today, despite the company announcing preliminary results that exceeded analysts' expectations for the fourth quarter ...

Below is Validea's guru fundamental report for INSPIRE MEDICAL SYSTEMS INC (INSP). Of the 22 guru strategies we follow, INSP rates highest using our P/B Growth Investor model based on the ...

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion. Shopify Posts Upbeat ...

Inspire Reports Year-over-Year Revenue Growth of 25% for the Fourth Quarter and 28% for the Full Year 2024 MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: ...

MINNEAPOLIS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, ...

Inspire Medical Systems, Inc. INSP announced preliminary revenues for the fourth quarter and full year 2024 yesterday. Despite the robust preliminary results, the company’s shares plunged nearly ...